拉丁美洲MRSA分离株中异质性万古霉素中介耐药性的检测
该研究评估了2006-08年和2011-14年从九个拉丁美洲国家收集的1189株万古霉素敏感MRSA分离株,通过糖肽补充琼脂筛选、Etest和宏量法检测hVISA表型,并用群体分析谱/AUC和全基因组测序进一步表征。结果显示39株(3.3%)为hVISA,其中95%属于CC5,多数携带WalK的Leu-14→Ile和VraT Glu-156→Gly氨基酸替换。结论认为hVISA在拉丁美洲频率较低,基于Etest的方法是可用的替代检测手段。
要点
- 拉丁美洲MRSA中hVISA表型频率为3.3%,2011-14年(5.6%)高于2006-08年(1.4%)。
- 95%的hVISA菌株属于CC5,90%携带WalK Leu-14→Ile和VraT Glu-156→Gly替换。
- 基于Etest的方法可作为检测hVISA临床分离株的重要替代方案。
核心结论
- 拉丁美洲MRSA中hVISA表型频率较低(3.3%),但2011-14年较2006-08年有升高趋势。
- hVISA菌株常见细胞包膜稳态和RNA合成相关蛋白的氨基酸替换,Etest法可作为检测hVISA的重要替代方法。
研究设计与样本
- 研究评估了2006-08年和2011-14年从九个拉丁美洲国家收集的1189株万古霉素敏感MRSA分离株。
- 先用糖肽补充琼脂策略初筛hVISA,再通过Etest(GRD)和宏量法(MET)检测,疑似hVISA菌株进行群体分析谱/AUC和全基因组测序。
主要发现
- 39株MRSA(3.3%)被归类为hVISA,2006-08年分离株中为1.4%,2011-14年分离株中为5.6%。
- 95%的hVISA菌株属于克隆复合体CC5。
- 仅6/39株hVISA通过PAP/AUC被归类为hVISA,另有6株接近临界值(0.87-0.89,临界值0.9)。
- 90%的hVISA菌株在WalK中携带Leu-14→Ile和VraT Glu-156→Gly氨基酸替换,并鉴定出10个仅存在于hVISA分离株的替换,涉及WalK、VraS、RpoB和RpoC蛋白。
临床怎么用
- 临床微生物实验室可考虑使用基于Etest的方法检测MRSA中的hVISA表型,以弥补常规药敏试验的不足。
- 对于CC5型MRSA感染,尤其当万古霉素疗效不佳时,应警惕hVISA可能。
局限性
- hVISA表型在拉丁美洲频率较低,研究结果可能受地区和时间范围限制。
- PAP/AUC确认的hVISA比例较低(6/39),部分菌株接近临界值,表型判定存在不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vancomycin is a common first-line option for MRSA infections. The heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) phenotype is associated with therapeutic failure. However, hVISA isolates are usually reported as vancomycin susceptible by routine susceptibility testing procedures. OBJECTIVES: To detect and characterize the hVISA phenotype in MRSA isolates causing infections in nine Latin American countries. METHODS: We evaluated a total of 1189 vancomycin-susceptible MRSA isolates recovered during 2006-08 and 2011-14. After an initial screening of hVISA using glycopeptide-supplemented agar strategies, the detection of hVISA was performed by Etest (GRD) and Macro-method (MET). Isolates deemed to be hVISA were subjected to population analysis profile/AUC (PAP/AUC) and WGS for further characterization. Finally, we interrogated alterations in predicted proteins associated with the development of the VISA phenotype in both hVISA and vancomycin-susceptible S. aureus (VSSA) genomes. RESULTS: A total of 39 MRSA isolates (3.3%) were classified as hVISA (1.4% and 5.6% in MRSA recovered from 2006-08 and 2011-14, respectively). Most of the hVISA strains (95%) belonged to clonal complex (CC) 5. Only 6/39 hVISA isolates were categorized as hVISA by PAP/AUC, with 6 other isolates close (0.87-0.89) to the cut-off (0.9). The majority of the 39 hVISA isolates exhibited the Leu-14→Ile (90%) and VraT Glu-156→Gly (90%) amino acid substitutions in WalK. Additionally, we identified 10 substitutions present only in hVISA isolates, involving WalK, VraS, RpoB and RpoC proteins. CONCLUSIONS: The hVISA phenotype exhibits low frequency in Latin America. Amino acid substitutions in proteins involved in cell envelope homeostasis and RNA synthesis were commonly identified. Our results suggest that Etest-based methods are an important alternative for the detection of hVISA clinical isolates.
引用
- Castro BE, Berrio M, Vargas ML, et al. Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America. J Antimicrob Chemother. 2020. PMID: 32562543. doi:10.1093/jac/dkaa221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。